A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Dose Ranging Study to Determine the Effect of Mepolizumab on Exacerbation Rates in Subjects with Severe Uncontrolled Refractory Asthma.

Grants and Contracts Details

StatusFinished
Effective start/end date12/12/09 → 9/30/12

Funding

  • GlaxoSmithKline: $96,119.00